Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

Väänänen T, Vuolteenaho K, Kautiainen H, Nieminen R, Möttönen T, Hannonen P, Korpela M, Kauppi MJ, Laiho K, Kaipiainen-Seppänen O, Luosujärvi R, Uusitalo T, Uutela T, Leirisalo-Repo M, Moilanen E; NEO-RACo Study Group.

PLoS One. 2017 Aug 25;12(8):e0183294. doi: 10.1371/journal.pone.0183294. eCollection 2017.

2.

Causal Evidence from Humans for the Role of Mediodorsal Nucleus of the Thalamus in Working Memory.

Peräkylä J, Sun L, Lehtimäki K, Peltola J, Öhman J, Möttönen T, Ogawa KH, Hartikainen KM.

J Cogn Neurosci. 2017 Dec;29(12):2090-2102. doi: 10.1162/jocn_a_01176. Epub 2017 Aug 4.

PMID:
28777058
3.

Successful management of super-refractory status epilepticus with thalamic deep brain stimulation.

Lehtimäki K, Långsjö JW, Ollikainen J, Heinonen H, Möttönen T, Tähtinen T, Haapasalo J, Tenhunen J, Katisko J, Öhman J, Peltola J.

Ann Neurol. 2017 Jan;81(1):142-146. doi: 10.1002/ana.24821. Epub 2016 Dec 28.

PMID:
27862207
4.

Early treatment intensification induces favourable radiographic outcomes according to predicted versus observed radiographic progression in early rheumatoid arthritis: a subanalysis of the randomised FIN-RACo and NEO-RACo trials.

Levitsky A, Wick MC, Möttönen T, Leirisalo-Repo M, Laasonen L, Korpela M, van Vollenhoven RF, Rantalaiho V.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1065-1071. Epub 2016 Aug 31.

PMID:
27607411
5.

Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2.

PMID:
27494516
6.

Imaging of Anterior Nucleus of Thalamus Using 1.5T MRI for Deep Brain Stimulation Targeting in Refractory Epilepsy.

Jiltsova E, Möttönen T, Fahlström M, Haapasalo J, Tähtinen T, Peltola J, Öhman J, Larsson EM, Kiekara T, Lehtimäki K.

Neuromodulation. 2016 Dec;19(8):812-817. doi: 10.1111/ner.12468. Epub 2016 Jul 11.

PMID:
27398710
7.

Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis.

Haavisto M, Saraste A, Pirilä L, Hannukainen JC, Kalliokoski KK, Kirjavainen A, Kemppainen J, Möttönen T, Knuuti J, Yli-Kerttula T, Roivainen A.

Rheumatology (Oxford). 2016 Oct;55(10):1777-85. doi: 10.1093/rheumatology/kew240. Epub 2016 Jun 21.

PMID:
27330160
8.

The Correlation between Intraoperative Microelectrode Recording and 3-Tesla MRI in Patients Undergoing ANT-DBS for Refractory Epilepsy.

Möttönen T, Katisko J, Haapasalo J, Tähtinen T, Saastamoinen A, Peltola J, Öhman J, Lehtimäki K.

Stereotact Funct Neurosurg. 2016;94(2):86-92. doi: 10.1159/000444761. Epub 2016 Apr 20.

PMID:
27093608
9.

Outcome based definition of the anterior thalamic deep brain stimulation target in refractory epilepsy.

Lehtimäki K, Möttönen T, Järventausta K, Katisko J, Tähtinen T, Haapasalo J, Niskakangas T, Kiekara T, Öhman J, Peltola J.

Brain Stimul. 2016 Mar-Apr;9(2):268-75. doi: 10.1016/j.brs.2015.09.014. Epub 2015 Oct 9.

10.

Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality.

Martelius T, Jalava J, Kärki T, Möttönen T, Ollgren J, Lyytikäinen O; Hospital Infection Surveillance team.

Infect Dis (Lond). 2016;48(3):229-34. doi: 10.3109/23744235.2015.1109135. Epub 2015 Nov 18.

PMID:
26577519
11.

Defining the anterior nucleus of the thalamus (ANT) as a deep brain stimulation target in refractory epilepsy: Delineation using 3 T MRI and intraoperative microelectrode recording.

Möttönen T, Katisko J, Haapasalo J, Tähtinen T, Kiekara T, Kähärä V, Peltola J, Öhman J, Lehtimäki K.

Neuroimage Clin. 2015 Mar 5;7:823-9. doi: 10.1016/j.nicl.2015.03.001. eCollection 2015.

12.

Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.

Valleala H, Korpela M, Hienonen-Kempas T, Immonen K, Lähteenmäki J, Uusitalo T, Komulainen R, Möttönen T, Hannonen P.

J Clin Rheumatol. 2015 Jan;21(1):24-30. doi: 10.1097/RHU.0000000000000166.

PMID:
25539430
13.

Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.

Rantalaiho V, Kautiainen H, Järvenpää S, Korpela M, Malmi T, Hannonen P, Kaipiainen-Seppänen O, Yli-Kerttula T, Möttönen T, Mustila A, Karjalainen A, Paimela L, Uutela T, Leirisalo-Repo M; NEO-RACo Study Group.

J Rheumatol. 2014 Dec;41(12):2379-85. doi: 10.3899/jrheum.140267. Epub 2014 Oct 1.

PMID:
25274892
14.

Immediate effects of deep brain stimulation of anterior thalamic nuclei on executive functions and emotion-attention interaction in humans.

Hartikainen KM, Sun L, Polvivaara M, Brause M, Lehtimäki K, Haapasalo J, Möttönen T, Väyrynen K, Ogawa KH, Öhman J, Peltola J.

J Clin Exp Neuropsychol. 2014;36(5):540-50. doi: 10.1080/13803395.2014.913554. Epub 2014 May 19.

15.

A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland.

Aaltonen KJ, Sokka T, Möttönen T, Korpela M, Komulainen R, Uusitalo T, Salomaa S, Uutela T, Valleala H, Rami Study Group.

Scand J Rheumatol. 2014;43(4):286-90. doi: 10.3109/03009742.2013.876512. Epub 2014 Mar 24.

PMID:
24654994
16.

Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.

PMID:
24297374
17.

Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Hannonen P, Kaipiainen-Seppänen O, Möttönen T, Kauppi M, Karjalainen A, Laiho K, Laasonen L, Hakola M, Peltomaa R, Leirisalo-Repo M; NEO-RACo Study Group.

Ann Rheum Dis. 2014 Nov;73(11):1954-61. doi: 10.1136/annrheumdis-2013-203497. Epub 2013 Aug 1.

PMID:
23908187
18.

Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial.

Rantalaiho VM, Kautiainen H, Korpela M, Hannonen PJ, Leirisalo-Repo M, Möttönen T; FIN-RACo Trial Group.

Ann Rheum Dis. 2013 May;72(5):786-8. doi: 10.1136/annrheumdis-2012-202737. Epub 2013 Jan 24. No abstract available.

PMID:
23349132
19.

Correlation of 18F-FDG PET/CT assessments with disease activity and markers of inflammation in patients with early rheumatoid arthritis following the initiation of combination therapy with triple oral antirheumatic drugs.

Roivainen A, Hautaniemi S, Möttönen T, Nuutila P, Oikonen V, Parkkola R, Pricop L, Ress R, Seneca N, Seppänen M, Yli-Kerttula T.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):403-10. doi: 10.1007/s00259-012-2282-x. Epub 2012 Nov 15.

PMID:
23229747
20.

Reduction in Clostridium difficile infections in Finland, 2008-2010.

Kanerva M, Mentula S, Virolainen-Julkunen A, Kärki T, Möttönen T, Lyytikäinen O; Hospital Infection Surveillance Team.

J Hosp Infect. 2013 Feb;83(2):127-31. doi: 10.1016/j.jhin.2012.09.021. Epub 2012 Nov 30.

PMID:
23201398
21.

Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.

Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S27-31. Epub 2012 Oct 16.

PMID:
23073350
22.

Consistency of assessments and willingness to pay for a reduction in morning symptoms over time in patients with rheumatoid arthritis.

Tuominen R, Tuominen S, Möttönen T.

Scand J Rheumatol. 2012;41(6):438-41. doi: 10.3109/03009742.2012.684699. Epub 2012 Sep 20.

PMID:
22994945
23.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
24.

Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8.

Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T, Korpela M, Möttönen T, Puolakka K.

Ann Rheum Dis. 2013 May;72(5):672-7. doi: 10.1136/annrheumdis-2011-200701. Epub 2012 Jun 7.

PMID:
22679306
25.

Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.

Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P.

Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29.

PMID:
21640044
26.

How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis?

Tuominen R, Tuominen S, Möttönen T.

Scand J Rheumatol Suppl. 2011;125:12-6. doi: 10.3109/03009742.2011.566435.

PMID:
21529305
27.

Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.

Rantalaiho V, Kautiainen H, Virta L, Korpela M, Möttönen T, Puolakka K.

Scand J Rheumatol. 2011 Jan;40(1):16-21. doi: 10.3109/03009742.2010.486768. Epub 2010 Aug 20.

PMID:
20726683
28.

[The goal for the treatment of rheumatoid arthritis should be remission].

Möttönen T, Mäkinen H, Puolakka K.

Duodecim. 2010;126(12):1457-64. Review. Finnish.

PMID:
20617749
29.

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.

Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group.

Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24.

30.

Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial.

Karstila KL, Rantalaiho VM, Mustonen JT, Möttönen TT, Hannonen PJ, Leirisalo-Repo M, Kaipiainen-Seppänen OA, Karjalainen AH, Korpela MM; FIN-RACo Trial Group.

Clin Exp Rheumatol. 2010 Jan-Feb;28(1):73-8.

PMID:
20346242
31.

Willingness to pay for improvement of physical function among rheumatoid arthritis patients as measured by Health Assessment Questionnaire.

Tuominen R, Azbel M, Hemmilä J, Möttönen T.

Rheumatol Int. 2011 Mar;31(3):347-52. doi: 10.1007/s00296-009-1280-1. Epub 2009 Dec 18.

PMID:
20020140
32.

[Rheumatoid arthritis (updated Current Care guideline)].

Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, Möttönen T, Varis T; Suomalaisen Lääkäriseuran Duodecimin ja Suomen Reumatologisen Yhdistyksen Asettama Työryhmä.

Duodecim. 2009;125(19):2131-2. Finnish.

PMID:
19938416
33.

Relative importance of the functional abilities comprising Health Assessment Questionnaire Disability Index among rheumatoid arthritis patients.

Tuominen R, Möttönen T, Suominen C, Vahlberg T, Tuominen S.

Rheumatol Int. 2010 Sep;30(11):1477-82. doi: 10.1007/s00296-009-1176-0. Epub 2009 Oct 14.

PMID:
19826820
34.

A mismatch between self-reported physical work load and the HAQ: early identification of rheumatoid arthritis patients at risk for loss of work productivity.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Hakala M, Viikari-Juntura E, Solovieva S, Arkela-Kautiainen M, Leirisalo-Repo M.

Clin Exp Rheumatol. 2009 May-Jun;27(3):422-9.

PMID:
19604434
35.

Perceived functional disabilities among rheumatoid arthritis patients.

Tuominen R, Tuominen S, Suominen C, Möttönen T, Azbel M, Hemmilä J.

Rheumatol Int. 2010 Mar;30(5):643-9. doi: 10.1007/s00296-009-1043-z. Epub 2009 Jul 11.

PMID:
19593569
36.

Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.

Valleala H, Korpela M, Möttönen T, Hienonen-Kempas T, Kauppi M, Hannonen P, Leirisalo-Repo M.

Scand J Rheumatol. 2009;38(5):323-7. doi: 10.1080/03009740902946355.

PMID:
19585384
37.

Community-associated methicillin-resistant Staphylococcus aureus isolated in Finland in 2004 to 2006.

Kanerva M, Salmenlinna S, Vuopio-Varkila J, Lehtinen P, Möttönen T, Virtanen MJ, Lyytikäinen O.

J Clin Microbiol. 2009 Aug;47(8):2655-7. doi: 10.1128/JCM.00771-09. Epub 2009 Jun 3.

38.

The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.

Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Järvenpää S, Leirisalo-Repo M, Hakala M, Puolakka K, Julkunen H, Luosujärvi R, Möttönen T; FIN-RACo Trial Group.

Arthritis Rheum. 2009 May;60(5):1222-31. doi: 10.1002/art.24447.

39.

Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis.

Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, Luukkainen R, Vuori K, Blåfield H, Leirisalo-Repo M.

Scand J Rheumatol. 2009 Mar-Apr;38(2):96-103. doi: 10.1080/03009740902756515.

PMID:
19274516
40.

Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.

Kauppi MJ, Neva MH, Laiho K, Kautiainen H, Luukkainen R, Karjalainen A, Hannonen PJ, Leirisalo-Repo M, Korpela M, Ilva K, Möttönen T; FIN-RACo Trial Group.

J Rheumatol. 2009 Feb;36(2):273-8. doi: 10.3899/jrheum.080429.

PMID:
19132793
41.

Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study.

Pikkarainen E, Lehtonen-Veromaa M, Möttönen T, Kautiainen H, Viikari J.

Contraception. 2008 Sep;78(3):226-31. doi: 10.1016/j.contraception.2008.05.002. Epub 2008 Jul 1.

PMID:
18692613
42.

Healthcare-associated infections in Finnish acute care hospitals: a national prevalence survey, 2005.

Lyytikäinen O, Kanerva M, Agthe N, Möttönen T, Ruutu P; Finnish Prevalence Survey Study Group.

J Hosp Infect. 2008 Jul;69(3):288-94. doi: 10.1016/j.jhin.2008.03.005. Epub 2008 Apr 25.

PMID:
18439716
43.

Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.

Hakala M, Risteli J, Aman S, Kautiainen H, Korpela M, Hannonen P, Leirisalo-Repo M, Laasonen L, Paimela L, Möttönen T; Fin-Raco Trial Group.

Scand J Rheumatol. 2008 Mar-Apr;37(2):90-3. doi: 10.1080/03009740701753689.

PMID:
18415764
44.

Exercise-induced training effects on bone mineral content: a 7-year follow-up study with adolescent female gymnasts and runners.

Pikkarainen E, Lehtonen-Veromaa M, Kautiainen H, Heinonen OJ, Viikari J, Möttönen T.

Scand J Med Sci Sports. 2009 Apr;19(2):166-73. doi: 10.1111/j.1600-0838.2008.00773.x. Epub 2008 Feb 17.

PMID:
18282222
45.

Prospective study on food fortification with vitamin D among adolescent females in Finland: minor effects.

Lehtonen-Veromaa M, Möttönen T, Leino A, Heinonen OJ, Rautava E, Viikari J.

Br J Nutr. 2008 Aug;100(2):418-23. doi: 10.1017/S0007114508894469. Epub 2008 Feb 14.

PMID:
18275625
46.

Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis.

Eklund KK, Leirisalo-Repo M, Ranta P, Mäki T, Kautiainen H, Hannonen P, Korpela M, Hakala M, Järvinen P, Möttönen T.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):684-9.

PMID:
18078614
47.

Ankylosing spondylitis: current approaches to treatment.

Toivanen A, Möttönen T.

BioDrugs. 1998 Sep;10(3):193-200.

PMID:
18020595
48.

Osteoporoosi.

Välimäki M, Alhava E, Aro H, Irjala K, Heinonen A, Hirvonen E, Jousilahti P, Komulainen J, Kröger H, Lamberg-Allardt C, Malmivaara A, Mattila K, Mervaala E, Möttönen T, Salmela P, Salmi J, Salovaara K, Savolainen A, Suominen H, Tuppurainen M, Viikari J; Suomalaisen Lääkäriseuran Duodecimin; Suomen Endokrinologiyhdistyksen; Suomen Gynekologiyhdistyksen Asettama Työryhmä.

Duodecim. 2007;123(11):1345-6. Finnish. No abstract available.

PMID:
17763654
49.

Cost of Finnish statutory inpatient rehabilitation and its impact on functional and work capacity of patients with early rheumatoid arthritis: experience from the FIN-RACo trial.

Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Pohjolainen T, Korpela M, Vuori K, Ilva K, Yli-Kerttula U, Järvinen P, Leirisalo-Repo M.

Scand J Rheumatol. 2007 Jul-Aug;36(4):270-7.

PMID:
17763204
50.

Disease activity score 28 as an instrument to measure disease activity in patients with early rheumatoid arthritis.

Mäkinen H, Kautiainen H, Hannonen P, Möttönen T, Korpela M, Leirisalo-Repo M, Luukkainen R, Puolakka K, Karjalainen A, Sokka T.

J Rheumatol. 2007 Oct;34(10):1987-91. Epub 2007 Jul 1.

PMID:
17611990

Supplemental Content

Loading ...
Support Center